iOmx Therapeutics AG

iOmx Therapeutics AG focuses on advanced/metastatic solid tumors and previously treated unresectable solid tumours, with clinical activity centred on patients whose disease has progressed after earlier therapy. The sponsored studies include evaluation of IOMX-0675 as a standalone antibody therapy and in combination with pembrolizumab.

• Metastatic solid tumor treatment
• Unresectable solid tumour management
• Anti-tumour immunotherapy
• Combination therapy with pembrolizumab

The research programme is directed toward tumour control in heavily pretreated disease settings across multiple solid tumour types.